Japan has long been viewed as a conservative M&A market, but recent dynamic and internationally engaged activity signals a more nuanced picture, particularly in licensing, co-development, and strategic collaboration structures. We expect transactional activity in the country’s life sciences and health care sector to be influenced by a combination of global deal trends and local considerations, with 2026 potentially seeing greater openness to transformational transactions, private equity participation, and reshaping of strategic portfolios.

We anticipate that Japan may emerge as a more credible market for sponsor-led life sciences platforms – rather than purely strategic trade deals – as exemplified by the recent acquisition of Mitsubishi Tanabe Pharma by Bain Capital, which was one of the largest private equity-led health care buyouts in Japanese history. We believe this deal demonstrates a growing confidence that Japanese pharmaceutical assets can be repositioned through focused investment, disciplined portfolio management, and more agile global strategy.

We further foresee that Japanese originators will continue actively to reshape their portfolios and that domestic companies more broadly may divest non-core assets while redeploying capital toward areas of long-term growth, including specialty and global markets. We may also increasingly see transactions in 2026 in which Japanese companies adopt a longer-term strategy to consolidate capabilities, sharpen therapeutic focus, and strengthen international reach. Given Japan’s increasing regulatory stability and improving development pathways, we predict that financial sponsors, activist investors, and infrastructure-style funds may become more active in pharmaceuticals, Contract Development and Manufacturing Organizations (CDMOs), and emerging biotechnology.

One notable trend is heightened scrutiny of IP and regulatory alignment in transactions. Buyers and partners are increasingly focused on inventorship integrity, patent scope, and freedom-to-operate in Japan, reflecting both tightened Japan Patent Office (JPO) practice and the practical impact of early enforcement risk. Weaknesses that might once have been addressed post-closing are now more likely to affect valuation or deal structure.

In licensing and alliance deals, we expect enhanced emphasis on Japan-specific development and commercial obligations. Global templates may often be insufficient, particularly where engagement with the regulator, pricing strategy, or supply commitments are critical to success. Accordingly, we are observing an increasing need for more tailored allocation of regulatory, IP, and lifecycle responsibilities.

Overall, life sciences and health care transactions in Japan increasingly reward thorough preparation and local insight. In 2026, we anticipate more sponsor-led carve-outs, strategic consolidation among mid-sized Japanese pharmaceutical companies, and increased licensing and co-development transactions, particularly in the biologics, infectious disease, and advanced therapy arenas. There is likely to be increased regulatory pragmatism and an emphasis on innovation, such that Japan will be increasingly positioned as a strategic jurisdiction where capital, technology, and long-term value creation intersect. We believe that companies and investors that combine strong local execution with global perspective may be best placed to capitalize on emerging opportunities.